These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10616177)

  • 21. Neurovirulence.
    Wood D
    Dev Biol Stand; 1999; 101():127-9. PubMed ID: 10566785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurovirulence testing of oral poliovaccine in the rhesus monkey.
    Arya SC
    Indian J Pathol Microbiol; 1976 Jul; 19(3):185-94. PubMed ID: 186408
    [No Abstract]   [Full Text] [Related]  

  • 23. An overview of vaccine vectors.
    Dorner F
    Dev Biol Stand; 1995; 84():23-32. PubMed ID: 7796959
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccines: World Health Organization versus Federal Drug Administration recommended formula.
    Khalil MK; al-Mazrou YY; al-Ghamdi YS
    East Mediterr Health J; 2000 Jul; 6(4):644-51. PubMed ID: 11794070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative monkey neurovirulence of Sabin type III poliovirus vaccines.
    Boulger LR; Marsden SA; Magrath DI; Taffs LF; Schild GC
    J Biol Stand; 1979 Apr; 7(2):97-111. PubMed ID: 225329
    [No Abstract]   [Full Text] [Related]  

  • 27. Polio vaccines and the cessation of vaccination.
    Minor PD
    Expert Rev Vaccines; 2003 Feb; 2(1):99-104. PubMed ID: 12901601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insertion of short hepatitis virus A amino acid sequences into poliovirus antigenic determinants results in viable progeny.
    Sverdlov ED; Tsarev SA; Markova SV; Rostapshov VM; Azhikina TL; Chernov IP; Gorbalenya AE; Kolesnikova MS; Romanova LI; Teterina NL
    FEBS Lett; 1989 Nov; 257(2):354-6. PubMed ID: 2479578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
    Minor PD; Dunn G; Ramsay ME; Brown D
    J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Live-attenuated strains of improved genetic stability.
    Macadam AJ; Ferguson G; Stone DM; Meredith J; Almond JW; Minor PD
    Dev Biol (Basel); 2001; 105():179-87. PubMed ID: 11763326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poliovirus vaccine strains in sewage and river water in South Africa.
    Pavlov DN
    Can J Microbiol; 2006 Aug; 52(8):717-23. PubMed ID: 16917529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virology. 'Biased' viruses suggest new vaccine strategy for polio and other diseases.
    Enserink M
    Science; 2008 Jun; 320(5884):1709. PubMed ID: 18583587
    [No Abstract]   [Full Text] [Related]  

  • 33. Public health. Is polio eradication realistic?
    Arita I; Nakane M; Fenner F
    Science; 2006 May; 312(5775):852-4. PubMed ID: 16690846
    [No Abstract]   [Full Text] [Related]  

  • 34. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.
    Neverov A; Chumakov K
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20063-8. PubMed ID: 21041640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
    Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
    J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Technical network for logistics in health (Technet).
    Wkly Epidemiol Rec; 1999 Apr; 74(17):129-35. PubMed ID: 10382370
    [No Abstract]   [Full Text] [Related]  

  • 37. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
    Dragunsky E; Nomura T; Karpinski K; Furesz J; Wood DJ; Pervikov Y; Abe S; Kurata T; Vanloocke O; Karganova G; Taffs R; Heath A; Ivshina A; Levenbook I
    Bull World Health Organ; 2003; 81(4):251-60. PubMed ID: 12764491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Problems with the oral polio vaccine.
    Bhasin VK
    Nat Med; 2008 Jan; 14(1):9. PubMed ID: 18180708
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.